The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
  • Tech
  • Bio
  • Companies
Mon, August 8, 2022 | 07:12
Tech
Janssen files patent suit against Samsung Bioepis
Posted : 2017-05-21 16:19
Updated : 2017-05-21 17:27
Print Preview
Font Size Up
Font Size Down
By Kang Seung-woo

Janssen Biotech has taken Samsung Bioepis to court in the U.S., accusing the Korean company of violating patents for its top-selling drug. Analysts said Sunday Janssen appeared to be trying to delay a Samsung biosimilar drug's entry into the U.S. market.

In April, Samsung won approval from the U.S. Food and Drug Administration to sell Renflexis -- its biosimilar of Janssen's blockbuster rheumatoid arthritis medicine Remicade. It was expected to go on sale in the world's largest pharmaceutical market late this year.

Samsung Bioepis said Janssen, a subsidy of healthcare conglomerate Johnson & Johnson, filed a lawsuit in the U.S. District Court of New Jersey last week, claiming Samsung has infringed on three of its patents. It also asks for damages. Remicade generates nearly $5 billion (5.59 trillion won) in sales a year.

"Janssen's patent lawsuit is an anticipated step. We will continue to proceed with the U.S. launch of Renflexis as planned," a Samsung official said. "Janssen takes issue with the same patents as it did with Celltrion's Inflectra."

Janssen last year filed a lawsuit against Celltrion, a cross-city rival of Samsung Bioepis, with another Remicade biosimilar named Inflectra. The Patent Trial and Appeal Board ruled in favor of the Korean company, which released the medicine in the U.S. market last November.

Observers expect that the legal action would not delay or prevent the U.S. market launch of the Samsung product, which Merck will take to market in November at the earliest.

Emailksw@ktimes.com Article ListMore articles by this reporter
 
LG
  • Citizens excited about refurbished Gwanghwamun Square
  • DSME hit with $970-million lawsuit from Japanese oil company
  • The fate of Sontag Hotel
  • [INTERVIEW] 'Taiwan is part of China,' says Chinese ambassador
  • Hyundai aims to develop own automotive semiconductors
  • Gov't considers slashing tariffs on imported produce ahead of Chuseok
  • KAI, Hanwha, SK, Hyundai Rotem contribute to Danuri project
  • Woori Bank to invest $7.7 million in 10 promising startups
  • 'Gov't should help manufacturers digitize fast to overcome global supply chain risks'
  • Envoy wary of creating Asian version of NATO
  • Interactive News
  • With tough love,
  • 'Santa dogs' help rebuild burnt forests in Andong
  • 'Santa dogs' help rebuild burnt forests in Andong
    • Brad Pitt to visit Korea to promote new film 'Bullet Train' Brad Pitt to visit Korea to promote new film 'Bullet Train'
    • [INTERVIEW] Jung Woo-sung was initially hesitant to take on role in 'Hunt' [INTERVIEW] Jung Woo-sung was initially hesitant to take on role in 'Hunt'
    • Hallyu research should be conducted beyond Korean perspective: scholars Hallyu research should be conducted beyond Korean perspective: scholars
    • 'The Red Sleeve' director debuts new thriller 'The Red Sleeve' director debuts new thriller
    • OTT platforms struggle amid declining number of users OTT platforms struggle amid declining number of users
    DARKROOM
    • Ice is melting, land is burning

      Ice is melting, land is burning

    • Tottenham 6-3 Team K League

      Tottenham 6-3 Team K League

    • Afghanistan earthquake killed more than 1,000

      Afghanistan earthquake killed more than 1,000

    • Divided America reacts to overturn of Roe vs. Wade

      Divided America reacts to overturn of Roe vs. Wade

    • Namaste: Yogis to celebrate International Yoga Day

      Namaste: Yogis to celebrate International Yoga Day

    The Korea Times
    CEO & Publisher : Oh Young-jin
    Digital News Email : webmaster@koreatimes.co.kr
    Tel : 02-724-2114
    Online newspaper registration No : 서울,아52844
    Date of registration : 2020.02.05
    Masthead : The Korea Times
    Copyright © koreatimes.co.kr. All rights reserved.
    • About Us
    • Introduction
    • History
    • Location
    • Media Kit
    • Contact Us
    • Products & Service
    • Subscribe
    • E-paper
    • Mobile Service
    • RSS Service
    • Content Sales
    • Policy
    • Privacy Statement
    • Terms of Service
    • 고충처리인
    • Youth Protection Policy
    • Code of Ethics
    • Copyright Policy
    • Family Site
    • Hankook Ilbo
    • Dongwha Group